Nxera Pharma To Receive Us$10 Million Milestone Payment From Abbvie Under Collaboration Targeting Neurological Diseases
30/06/2026 07:33
BRIEF-Nxera Pharma Co Ltd - Nxera Pharma To Receive Us$10 Million Milestone Payment From Abbvie Under Collaboration Targeting Neurological Diseases June 30 (Reuters) - Nxera Pharma Co Ltd 4565.T:
NXERA PHARMA CO LTD: NXERA PHARMA TO RECEIVE US$10 MILLION MILESTONE PAYMENT FROM ABBVIE UNDER COLLABORATION TARGETING NEUROLOGICAL DISEASES
Source text: ID:nTSrd8eaa1
Further company coverage: 4565.T
(Reporting by Tokyo Newsroom)
((+81345201189;))
Recent news on Nxera Pharma
See all newsNxera Pharma Submits Marketing Authorization Application For Vamorolone In South Korea For Treatment Of Duchenne Muscular Dystrophy
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Nxera Pharma - Entered Into Exclusive License, Supply And Commercialization Agreement With Synmosa For Quviviq Across Eight Asia-Pacific Markets
Brief: Nxera Announces Successful Resolution Of Minig Patent Infringement Action
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up